A Europe-wide assessment of antibiotic resistance rates in Bacteroides and Parabacteroides isolates from intestinal microbiota of healthy subjects by Sóki, József et al.
lable at ScienceDirect
Anaerobe 62 (2020) 102182Contents lists avaiAnaerobe
journal homepage: www.elsevier .com/locate/anaerobeAntimicrobial susceptibility of anaerobic bacteriaA Europe-wide assessment of antibiotic resistance rates in Bacteroides
and Parabacteroides isolates from intestinal microbiota of healthy
subjects
Jozsef Soki a, *, Ingrid Wybo b, Edit Hajdú c, Nurver Ulger Toprak d, Samo Jeverica e,
Catalina-Suzana Stingu f, Daniel Tierney g, John David Perry g, Maria Matuz h, Edit Urban a,
Elisabeth Nagy a, On behalf of the ESCMID Study Group on Anaerobic Infections
a Institute of Clinical Microbiology, Faculty of Medicine, University of Szeged, Szeged, Hungary
b Department of Microbiology and Infection Control, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Belgium
c Division of Infectious Diseases, First Department of Internal Medicine, Faculty of Medicine, University of Szeged, Szeged, Hungary
d Department of Microbiology, Marmara University Medical School, Istanbul, Turkey
e Institute of Microbiology and Immunology, University of Ljubljana, Ljubljana, Slovenia
f Institute for Medical Microbiology and Epidemiology of Infectious Diseases, University Hospital of Leipzig, Leipzig, Germany
g Microbiology Department, Freeman Hospital, Newcastle Upon Tyne, UK
h Department of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungarya r t i c l e i n f o
Article history:
Received 29 November 2019
Received in revised form
25 February 2020
Accepted 26 February 2020
Available online 29 February 2020
Handling editor: Lyudmila Boyanova
Keywords:
Antibiotic resistance
Bacteroides
B. fragilis
Bacteroides choromogenic agar
Intestinal
Parabacteroides* Corresponding author. Institute of Clinical Microb
Clinical Centre, Faculty of Medicine, University of Sze
Szeged, Hungary.
E-mail address: soki.jozsef@med.u-szeged.hu (J. So
https://doi.org/10.1016/j.anaerobe.2020.102182
1075-9964/© 2020 Elsevier Ltd. All rights reserved.a b s t r a c t
Here, we sought to assess the levels of antibiotic resistance among intestinal Bacteroides and Para-
bacteroides strains collected between 2014 and 2016 in Europe and also attempted to compare resistance
levels between clinical and commensal isolates. Bacteroides and Parabacteroides isolates were recovered
from faecal samples via the novel Bacteroides Chromogenic Agar (BCA) method. Antibiotic susceptibilities
were determined by agar dilution for ten antibiotics. The values obtained were then statistically eval-
uated. Altogether 202 Bacteroides/Parabacteroides isolates (of which 24, 11.9%, were B. fragilis) were
isolated from the faecal specimens of individuals taken from five European countries. The percentage
values of isolates resistant to ampicillin, amoxicillin/clavulanate, cefoxitin, imipenem, clindamycin,
moxifloxacin, metronidazole, tetracycline, tigecycline and chloramphenicol were 96.6, 4.5, 14.9, 2.0, 47.3,
11.4, 0, 66.2, 1.5 and 0%, respectively. These values are close to those reported in the previous European
clinical Bacteroides antibiotic susceptibility survey except for amoxicillin/clavulanate and clindamycin,
where the former was lower and the latter was higher in normal microbiota isolates. To account for these
latter findings and to assess temporal effects we compared the data specific for Hungary for the same
period (2014e2016), and we found differences in the resistance rates for cefoxitin, moxifloxacin and
tetracycline.
© 2020 Elsevier Ltd. All rights reserved.1. Introduction
The related genera of Bacteroides and Parabacteroides, which
previously formed the B. fragilis group belonging to the Bacter-
oidetes phylum, are important opportunistic anaerobic pathogens.
They are also important members of the human and mammalianiology, Albert Szent-Gy€orgyi
ged, Semmelweis 6, H-6726,
ki).normal intestinal microbiota that, together with the Prevotella and
the Firmicutes species, constitute themost common taxa in the gut.
With their abundance they are an indispensable part of it and
contribute to the healthy function of the gut [1]. Earlier microbio-
logical investigations confirmed their role in colonisation resis-
tance, commensalism, production of nutrients and the maturation
of the gut [1]. Also, the application of next-generation sequencing
methods has aided the analysis of the role of the gut microbiome in
various healthy and diseased states by revealing a contribution to
disorders such as obesity, diabetes, inflammatory bowel syndrome
and other autoimmune diseases [2]. Studies have confirmed the
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consistent patterns (enterotypes) [3]. The gene content of the
microbiota exceeds the number of host genes [4] and it exerts
complex metabolic, nutritional, microbiological, ecological and
immunological interactions. It has been shown experimentally that
the B. fragilis group contributes to these interactions by digestion
capabilities [5,6] and the modulation of the immune system by
their capsular polysaccharides [7,8].
However, the mechanisms by which their commensalism and
virulence are regulated together are not known. Their potential for
pathogenicity is exacerbated by the fact that ‘B. fragilis group spe-
cies’ are the most antibiotic resistant among all pathogenic anaer-
obes in terms of resistance prevalence and the number of resistance
mechanisms [9]. Regular susceptibility surveys have been con-
ducted to estimate antibiotic susceptibility both spatially and
temporally. From these studies it is possible to monitor the evolu-
tion of their resistance mainly in Europe and the USA, and it has
been shown that (i) there are very high resistance rates for peni-
cillins, cephalosporins and tetracyclines (about 70e99%); (ii) in-
termediate levels of resistance are common for cephamycins,
clindamycin, moxifloxacin and some b-lactam/b-lactamase inhibi-
tor combinations which are subject to changes in antibiotic usage
and (iii) carbapenems, metronidazole and tigecycline remain very
effective and seem almost unaffected by their usage rates [10]. Also,
genomic investigations have demonstrated that Bacteroides species
may be reservoirs of antibiotic resistance genes [11].
We sought to determine the susceptibility rates of the normal
Bacteroides microbiota in European citizens with possible impli-
cations for treatment of infections thatmay arise from this flora and
compare these with the antibiotic resistance rates of isolates from
clinical cases. Here, we report our results on the antibiotic sus-
ceptibilities of 202 B. fragilis group isolates obtained from the
normal flora of individuals living in five European countries.
2. Materials and methods
2.1. Subjects
During 2014e2016 stool samples taken from healthy donors
(n ¼ 42) who did not have an enteric disease and had not received
any antibiotic therapy for at least 3 months prior to the tests, were
taken in Belgium (n ¼ 5), Germany (n ¼ 5) Hungary (n ¼ 12),
Slovenia (n ¼ 8) and Turkey (n ¼ 12).
2.2. Bacterial isolates
The following protocol was used for the isolation of Bacteroides
and Parabacteroides strains from stool samples. Approximately
5mg (one small loopful) of faecal material was suspended in 1ml of
brain heart infusion (BHI) broth and then diluted 102- and 104-fold
by sequentially adding 50 mLe4950 ml of BHI broth and plating
100 ml aliquots on the surface of the novel selective Bacteroides
chromogenic agar (BCA) plates with (BCA-A) or without (BCA-B)
4 mg/L meropenem [12]. The plates were incubated anaerobically
at 37 C for 48 h. Afterwards the approximate numbers of colonies
grown were estimated and 3e8 colonies with different colony
morphologies were selected and subcultured on anaerobic Schae-
dler and Columbia Blood agars and incubated with standard
anaerobiosis (48 h) and aerobiosis (overnight), respectively. The
strains isolated in Belgium, Germany, Slovenia and Turkey were
transported to the Szeged laboratory in ESwab 480C transport
tubes (COPAN Diagnostics Inc., USA) at ambient temperature by
courier firms in compliance with international safety regulations
for transport of biological materials. After referral to Szeged,
Hungary, strains were subcultured immediately, speciesidentifications were carried out via the MALDI-TOF MS method
(Microflex LP instrument and Biotyper 3.1 software package, Bruker
Daltonics, Bremen, Germany) [13]. Identifications were accepted if
the log scores were2.0. If the log scores were <2.0, then 16S rDNA
sequencing was applied to determine species identification. We
also used MALDI-TOF MS to determine which genetic divisions
(Division I e carbapenemase/cfiA-negative or Division II e carba-
penemase/cfiA-positive) the B. fragilis strains belonged to Refs. [14].
The long-term storage of the Bacteroides or Parabacteroides isolates
was achieved in BHI broth containing 20% glycerol at 70 C.
The regular cultivation of the isolates in Szeged, Hungary, was
performed on Columbia agar supplemented with 5% sheep blood,
0.6 g/L cysteine and 1 mg/L vitamin K1 in an anaerobic cabinet
(Concept 400, Ruskinn Technology Ltd., Bridgend, UK) with an at-
mosphere of 70% N2, 10% H2 and 5% CO2.
Overall, 202 Bacteroides/Parabacteroides isolates (9 B. caccae, 6
B. cellulosilyticus, 7 B. clarus/stercoralis, 1 B. coprocola, 4 B. eggerthii, 1
B. faecis, 4 B. finegoldii, 24 B. fragilis, 3 B. intestinalis, 2 B. nordii, 48
B. ovatus/xylanisolvens, 7 B. stercoris, 19 B. thetaiotaomicron, 14
B. uniformis, 36 B. vulgatus/dorei, 12 P. distasonis, 4 P. johnsonii and 1
P. merdae) were collected and the species distribution by country is
given in the Supplementary data (see Table S1).
2.3. Determination of antibiotic susceptibilities
The standard agar dilution technique was used to measure
antibiotic susceptibilities as recommended by the CLSI using
antibiotic-supplemented Brucella agar inoculated with around
5  105 cells [10,15]. The following antibiotics were tested: ampi-
cillin, amoxicillin/clavulanate, cefoxitin, imipenem, clindamycin,
moxifloxacin, metronidazole, tetracycline, tigecycline and chlor-
amphenicol. For quality control, B. fragilis ATCC 25285 and
B. thetaiotaomicron ATCC 29741 were included. Where available,
EUCAST resistance breakpoints were applied (>2, >8, >8, >4
and > 4 mg/L for ampicillin, amoxicillin/clavulanate, imipenem,
clindamycin and metronidazole) [16]. Where EUCAST breakpoints
were unavailable, CLSI breakpoints (>32, >4, >8, >8 and > 16 mg/L
for cefoxitin, moxifloxacin, tetracycline, tigecycline and chloram-
phenicol) [15] were applied to categorize resistance.
2.4. 16S rDNA sequencing
For PCR amplification, template DNA preparations were pre-
pared by the boiling method. Stated briefly, one small loopful of
colonies grown anaerobically on Columbia blood agar plates was
suspended in 100 ml of sterile distilled water to give a 0.5McFarland
density, incubated at 99.5 C in a dry bath for 12 min and centri-
fuged at 14,000 rpm for 2 min then the supernatant stored
at 25 C until use. For 16S rDNA sequencing the E8F (AGAGTTT-
GATCCTGGCTCAG) and the E533R (TIACCGIIICTICTGGCAC) primers
(0.7 mM) were used in 50 ml PCR volumes containing 25 ml PCR
master mix (2x, DreamTaq, Fermentas) and 5 ml template DNA us-
ing the following cycling conditions: 95 C 2 min 30 s; 95 C 14 s,
56 C 20 s, 72 C 1min 35x; 72 C 7min. The products were cleaned
using a PCR Cleanup Kit and processed via the BigDye Terminator
v3.1 Cycle Sequencing Kit with the 3500 Series Genetic Analyzer
(LifeTechnologies). The nucleotide sequences obtained were
blasted to records of type strains in GenBank for species identifi-
cation [17].
2.5. Statistical evaluation
The data set collected in this study was analysed via Spearman
rank correlation or compared with the data of the clinical isolates
obtained earlier by c2-tests (resistance data) or variance analyses
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(Kruskal-Valis method) and using the Sigmaplot 12 software
package (Sigmaplot, Germany). The significance level was set to
0.05.3. Results and discussion
3.1. The isolation of intestinal Bacteroides and Parabacteroides
strains from the stool samples of healthy subjects
The cultivation of Bacteroides/Parabacteroides isolates from stool
samples using BCA plates yielded a total of 202 isolates from five
European countries (the complete distribution is shown in Table S1,
and non-targeted isolates are listed in the Supplementary mate-
rial). The approximate numbers of CFU for Bacteroides and Para-
bacteroides calculated for 1 g of faecal material among Hungarian
patients were 2.6  107 (SD ¼ 3.18  107) and 1.41  109
(SD ¼ 1.83  109) on BCA plates with and without meropenem,
respectively, indicating that Bacteroides isolates with elevated
meropenem MICs are not infrequent in the faecal microbiome (but
about 2 orders of magnitude less than the susceptible isolates). The
species distribution listed in Table S1 may reflect the real situation
in the colon as non-fragilis Bacteroides (NFB) species were prevalent
and the proportion of B. fragilis was only 11.9%. The B. clarus/ster-
coralis, ovatus/xylanisolvens and vulgatus/dorei pairs were not
resolved since they had not been distinguished in the previous
reference study [10]. The number of bacterial cells in faecal material
is estimated to be around 1011/g and the proportion of Bacteroides is
around 30% in faecal material, hence roughly 3  1010/g Bacteroides
cells can be expected there. In this study wewere able to recover an
average of 1.41  109 Bacteroides per gram of sample; and about 5%
of this theoretical value, which can be explained by the fact that notTable 1
Antibiotic susceptibility data of normal flora B. fragilis group isolates obtained from Euro
Country Antibiotic MICs (mg/L) R (%)
Range MIC50 MIC90
Alla Ampicillin 1->256 128 >256 96.6
Amoxicillin/clavulanate 0.064e32 0.5 4 4.5
Cefoxitin 0.5e256 16 64 14.9
Imipenem 0.032e324 0.5 2 2.0
Clindamycin 0.064->256 4 >256 47.3
Moxifloxacin 0.064e64 1 8 11.4
Metronidazole 0.032e4 0.5 1 0
Tetracycline 0.064->256 32 128 66.2
Tigecycline 0.032e32 0.5 4 1.5
Chloramphenicol 0.125e8 4 8 0
Belgium Ampicillin 8->256 256 >256 100
Amoxicillin/clavulanate 0.125e16 1 4 3.4
Cefoxitin 0.5e256 4 128 20.3
Imipenem 0.064e0.5 0.5 0.5 6.8
Clindamycin 0.125->256 16 >256 62.7
Moxifloxacin 0.125e64 1 16 25.4
Metronidazole 0.064e0.5 0.5 0.5 0
Tetracycline 0.5->256 32 64 71.2
Tigecycline 0.032e32 1 8 3.4
Chloramphenicol 0.125e8 8 8 0
Germany Ampicillin 4 > 256 32 >256 100
Amoxicillin/clavulanate <0.016e0.5 0.125 0.5 0
Cefoxitin 1e128 16 128 29.2
Imipenem 0.064e4 0.5 2 0
Clindamycin 0.125->256 64 >256 87.5
Moxifloxacin 0.064e32 2 16 20.8
Metronidazole 0.064e4 0.5 1 0
Tetracycline 0.125e128 32 128 75.0
Tigecycline <0.016e16 0.5 2 4.2
Chloramphenicol 0.5e4 8 8 0
a From all the given countries.all Bacteroides isolates/species are oxygen tolerant or there were
also dead cells. A study that reported live cell counts in the rabbit
intestinal tract, appeared recently and it demonstrated that dead
cells are also present there [18]. The ratio of B. fragilis isolates
among the total of Bacteroides isolates recovered was 11.9%, which
was similar to that found by Møller-Hansen et al. [19]. This once
again confirmed that NFB isolates are more abundant than B. fragilis
in the intestinal normal flora, but the actual proportion of the
B. fragilis living cells is also significant and was higher than earlier
thought (by 0.5e10%) [1].3.2. Determination of the antibiotic susceptibilities of intestinal
Bacteroides and Parabacteroides isolates
The antibiotic susceptibilities for ampicillin, amoxicillin/clav-
ulanate, cefoxitin, imipenem, clindamycin, moxifloxacin, metroni-
dazole, tetracycline, tigecycline and chloramphenicol were
recorded for the 202 B. fragilis group isolates recovered from the
normal microbiota by agar dilution. Tetracycline and chloram-
phenicol were included as they may be considered as a choice for
treating infections caused by strains that are resistant to more
conventional agents. Country-specific data values are displayed in
Table 1 and cumulative data values are displayed in Table 2 with the
MIC range, MIC50, MIC90 and the resistance rates. The cross-
correlations between pairs of antibiotics are given in the Supple-
mentary material.
There were some isolates, 17 (8.5%) and 5 (2.5%, Table S3), that
had a resistance to >3 or 5 antibiotics, respectively. In Hungary, in a
recent antibiotic resistance survey, the prevalence of MDR Bacter-
oides strains was estimated to be 1.5% (6/400) [20], but we have no
prevalence data on MDR Bacteroides from other countries that
participated in this study. Also, no isolates were recovered that hadpe.
Country Antibiotic MICs (mg/L) R (%)
Range MIC50 MIC90
Hungary Ampicillin 2->256 128 >256 99.0
Amoxicillin/clavulanate 0.064e32 1 8 6.2
Cefoxitin 0.5e128 32 128 31.2
Imipenem 0.064e16 0.5 4 3.1
Clindamycin 0.064->256 2 >256 35.4
Moxifloxacin 0.064e64 1 8 6.2
Metronidazole 0.032e4 0.5 1 0
Tetracycline 0.125e128 16 32 66.7
Tigecycline 0.032e8 0.25 2 0
Chloramphenicol 0.25e8 4 8 0
Slovenia Ampicillin <2>256 32 256 90.9
Amoxicillin/clavulanate 0.064e2 0.225 1 0
Cefoxitin 0.5e32 16 32 0
Imipenem 0.064e16 0.5 1 4.5
Clindamycin 0.064e8 4 8 0
Moxifloxacin 0.064->32 2 4 4.2
Metronidazole 0.064e1 0.5 1 0
Tetracycline 0.064e128 8 32 45.4
Tigecycline 0.125e4 0.5 4 0
Chloramphenicol 0.125e8 8 8 0
Turkey Ampicillin <2>256 64 >256 87.5
Amoxicillin/clavulanate 0.064e16 0.5 2 2.5
Cefoxitin 0.5e128 16 32 5.0
Imipenem 0.032e2 0.5 1 0
Clindamycin 0.064->256 4 >256 40.0
Moxifloxacin 0.064e64 2 32 20.0
Metronidazole 0.064e0.5 0.5 0.5 0
Tetracycline 0.064e128 64 128 85.0
Tigecycline 0.032e16 0.25 4 2.5
Chloramphenicol 0.25e8 2 4 0
Table 2
Comparison of the antibiotic susceptibility parameters of clinical and normal flora B. fragilis group isolates obtained in Europe.
Antibiotic/taxon Clinical isolatesa Intestinal isolatesb pd
MICs (mg/L) R (%) MICs (mg/L) R (%)
Range MIC50 MIC90 Range MIC50 MIC90
Ampicillin
All isolatesc 1->256 32 >256 98.2 1->256 128 >256 96.6 n.s.e
B. fragilis 1->256 32 >256 97.4 4->256 32 >256 100 n.s.
B. thetaiotaomicron 2->256 64 >256 98.8 4->256 >256 >256 100 n.s.
B. ovatus 8->256 64 >256 100 1->256 64 >256 95.8 n.s.
B. vulgatus 4->256 64 >256 100 1->256 128 >256 94.3 n.s.
B. uniformis 16->256 32 >256 100 1->256 128 >256 90.9 n.s.
P. distasonis 8->256 16 >256 100 8->256 >256 >256 100 -f
Other species 4->256 64 >256 100 1->256 256 >256 94.1 n.s.
Amoxicillin/clavulanic acid
All isolates 0.016->256 1 16 10.4 0.064e32 0.5 4 4.5 0.021
B. fragilis 0.016->256 1 16 8.7 0.064e16 0.5 8 4.2 n.s.
B. thetaiotaomicron 0.125e32 1 16 12.0 0.064e16 1 4 5.3 n.s.
B. ovatus 0.25e32 1 16 18.4 0.064e16 0.5 4 4.2 n.s.
B. vulgatus 0.125e256 1 16 14.3 0.064e2 0.55 1 0 0.022
B. uniformis 0.125e64 1 64 30.0 0.064e8 2 8 0 n.s.
P. distasonis 0.5e256 2 32 21.4 0.064e32 2 32 23.1 n.s.
Other species 0.125e64 2 16 11.5 0.064e16 0.5 4 3.9 n.s.
Cefoxitin
All isolates 1->256 16 128 17.2 0.5e256 16 64 14.9 n.s.
B. fragilis 1->256 16 256 13.7 1e32 16 32 0 0.031.
B. thetaiotaomicron 2->256 32 256 27.1 4e128 32 128 31.6 n.s.
B. ovatus 1e256 32 256 24.5 0.5e128 16 64 12.5 n.s.
B. vulgatus 1->256 8 64 14.3 1e128 16 64 14.3 n.s.
B. uniformis 2e256 8 256 20.0 0.5e128 16 128 18.2 n.s.
P. distasonis 8->256 32 >256 35.7 0.5e128 8 128 23.1 n.s.
Other species 2->256 16 >256 26.9 0.5e128 8 64 15.7 n.s.
Imipenem
All isolates 0.002->32 0.5 1 0.85 0.032e324 0.5 2 2.0 n.s.
Strains isolated on BCA-B 0.032e32 0.5 1 1.4 n.s.
B. fragilis 0.002->32 0.25 0.5 1.2 0.064e16 0.5 16 13.6 <0.001
Strains isolated on BCA-B 0.125e16 0.5 1 10.5 0.02.
B. thetaiotaomicron 0.047e8 0.25 1 0 0.25e2 1 2 0 e
B. ovatus 0.016e2 0.25 1 0 0.064e16 0.5 4 2.1 n.s.
B. vulgatus <0.125e2 0.125 0.5 0 0.064e16 0.5 2 2.9 n.s.
B. uniformis 0.125e2 0.125 1 0 0.064e1 0.5 1 0 e
P. distasonis 0.125e2 0.5 1 0 0.25e2 1 2 0 e
Other species 0.012e8 0.5 4 0 0.064e4 0.5 2 0 e
Clindamycin
All isolates 0.016->256 2 >256 32.4 0.064->256 4 >256 47.3 <0.001
B. fragilis 0.016->256 1 256 28.5 0.125->256 2 >256 20.8 n.s.
B. thetaiotaomicron 0.047->256 4 >256 42.2 0.064->256 8 >256 63.2 ns.
B. ovatus 0.125->256 4 >256 44.9 0.064->256 4 >256 45.8 n.s.
B. vulgatus 0.016->256 2 >256 47.6 0.064->256 4 >256 48.6 n.s.
B. uniformis 1->256 8 256 60.0 0.25->256 128 >256 63.6 n.s.
P. distasonis 0.016->256 1 >256 28.6 0.064->256 8 >256 53.9 n.s.
Other species 0.047->256 2 256 34.6 0.064->256 8 >256 49.0 n.s.
Moxifloxacin
All isolates <0.125e32 1 16 13.6 0.064e64 1 8 11.4 n.s.
B. fragilis <0.125e64 0.5 8 14.0 0.064e4 0.5 2 0 0.032
B. thetaiotaomicron 0.125e32 1 16 14.5 0.5e16 2 8 10.5 n.s.
B. ovatus <0.125e32 1 4 8.2 0.064e64 1 8 8.3 n.s.
B. vulgatus <0.125e64 1 32 21.4 0.064e64 2 32 11.4 n.s.
B. uniformis <0.125e4 1 4 0 0.064e32 4 32 45.5 0.023
P. distasonis <0.125e2 0.5 1 0 0.25e16 0.5 16 30.8 0.048
Other species <0.125e32 0.25 4 11.5 0.064e64 1 4 7.8 n.s.
Metronidazole
All isolates 0.016e256 0.5 1 0.5 0.5e1 0.5 1 0 n.s.
B. fragilis 0.016e32 0.5 1 0.5 0.064e4 0.5 1 0 n.s.
B. thetaiotaomicron <0.125->256 0.5 2 1.2 0.064e2 0.5 1 0 n.s.
B. ovatus 0.032e2 0.5 2 0 0.064e4 0.5 1 0 e
B. vulgatus <0.125e4 0.5 1 0 0.064e4 0.5 1 0 e
B. uniformis 0.016e2 0.5 1 0 0.032e1 0.5 1 0 e
P. distasonis 0.125e2 0.5 1 0 0.064e0.5 0.5 0.5 0 e
Other species <0.125e4 0.5 2 0 0.064e2 0.5 1 0 e
Tetracycline
All isolates 0.064->256 32 128 66.2
B. fragilis 0.125e128 32 128 58.3
B. thetaiotaomicron 0.064e256 32 128 89.5
B. ovatus 0.125e128 16 64 52.1
B. vulgatus 0.125e128 32 128 88.6
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Table 2 (continued )
Antibiotic/taxon Clinical isolatesa Intestinal isolatesb pd
MICs (mg/L) R (%) MICs (mg/L) R (%)
Range MIC50 MIC90 Range MIC50 MIC90
B. uniformis 0.064e128 32 128 63.6
P. distasonis 0.5e32 16 64 69.2
Other species 0.125e64 32 32 58.8
Tigecycline
All isolates 0.016e32 0.25 2 1.7 0.032e32 0.5 4 1.5 n.s.
B. fragilis 0.016e32 0.5 2 1.8 0.064e8 2 4 0 n.s.
B. thetaiotaomicron 0.064e8 0.25 0.5 0 0.064e32 1 4 5.3 n.s.
B. ovatus 0.032e16 0.25 2 2.0 0.064e16 0.25 8 2.1 n.s.
B. vulgatus <0.125e16 2 4 4.8 0.064e16 0.25 2 2.9 n.s.
B. uniformis 0.016e16 0.125 1 10.0 0.032e2 0.064 8 0 n.s.
P. distasonis 0.125e4 0.5 2 0 0.125e4 0.5 2 0 e
Other species 0.047e8 0.125 1 0 0.032e8 0.5 2 0 e
Chloramphenicol
All isolates 0.125e8 4 8 0
B. fragilis 4e8 4 8 0
B. thetaiotaomicron 1e8 8 8 0
B. ovatus 0.125e8 4 8 0
B. vulgatus 0.125e8 4 8 0
B. uniformis 0.5e8 4 8 0
P. distasonis 0.25e8 2 8 0
Other species 0.125e8 4 8 0
a From Ref. [10].
b Data from this study.
c All Bacteroides and Parabacteroides species.
d The significance values of differences obtained by c2-tests (significances are given in bold).
e Here, n. s. means non-significant.
f Equal values.
J. Soki et al. / Anaerobe 62 (2020) 102182 5a resistance to both imipenem and metronidazole or both imipe-
nem and tigecycline.
3.3. A comparison of our new data with the antibiotic susceptibility
data in the previous European study on clinical Bacteroides isolates
The findings of this study were also compared with those of the
clinical isolates in the latest European Bacteroides susceptibility
survey [10] (see Table 2), using regular epidemiological parameters
such as MIC range, MIC50, MIC90 and the resistance rate. Our
comparison of resistance data for the normal microbiota and clin-
ical isolates tells us that the general trends are similar for both
intestinal and clinical isolates: almost 100% resistance for ampi-
cillin, intermediate rates of resistance (13e44%) for moxifloxacin,
cefoxitin and clindamycin and very low resistance rates (0e4%) for
amoxicillin/clavulanate, imipenem, metronidazole and tigecycline
[10,21]. The resistance rate of the B. fragilis group isolates for
tetracycline was 69.7%, which is close to that (75.9%) for clinical
isolates obtained recently in Romania [22]. No chloramphenicol-
resistant strain was found and this is consistent with the findings
of other studies. However, at present there is a scarcity of data for
these two last antibiotics.
In addition, a systematic analysis using the c2-test to compare
the resistance rates of clinical isolates and the normal microbiota
revealed statistically significant differences for amoxicillin/clav-
ulanate (decreased resistance) and clindamycin (increased resis-
tance); see Table 1. For B. fragilis isolates. Higher resistance rates
were found for imipenem irrespective of whether they were iso-
lated on BCA-A or BCA-B plates (Table 1). Statistically different
resistance rates were found with some species for some antibiotics,
but high significance values (<0.001) were only found for clinda-
mycin for all Bacteroides/Parabacteroides isolates and for imipenem
in the case of B. fragilis, regardless of which BCA plate typewas used
for the isolation (Table 1). Some earlier studies also assessed the
antibiotic susceptibility of Bacteroides isolates obtained from
normal microbiota and reported similar results to those for clinicalisolates. However, it should also be mentioned that these studies
were different in various respects, such as the taxa involved,
anatomical sites of isolation and the age and health of the subjects
[19,23e29]. They also did not include comparisons with isolates
from infections and examined fewer strains than ours; hence a
clear conclusion could not be drawn. But Hansen et al. reported that
carbapenem therapy significantly increased the number of
carbapenem-resistant strains recovered from patient’s faecal sam-
ples [19].
The differences found in resistance in our study might be
accounted by the following factors: (i) the resistance data simply
changed over the time that had elapsed between the two studies
(2008e10 and 2014e16); (ii) because of differences between
countries and different species composition; and (iii) there were
real differences in antibiotic resistance between the clinical and
normal microbiota isolates.
As there were country- and species-specific differences in the
resistance data (Table S2) we think that temporal changes were
probably chiefly responsible for the observed differences. This is
supported by the fact that if we plot the fairly constant clindamycin
consumption against the resistance percentage in Hungary an in-
crease in resistance can be seen (Fig. S1). This may be explained by
models showing that above a certain threshold of antibiotic use, an
increase in the resistance rate can be expected regardless of
whether the usage increases further [30].
However, if we also compare the data from Hungary from this
study with the antibiotic susceptibilities of a parallel study on
clinical Bacteroides isolates also obtained fromHungary in the same
period of time [31], we observe differences for cefoxitin, moxi-
floxacin and tetracycline (Table S4). In our opinion this means that
the difference depends on the isolation sites, e.g. fecal microbiota
versus clinical isolates. Recently differences were found in the
microbial compositions of the mucosa and lumen of the small
bowel, large bowel and feces of humans and this may indicate that
the antimicrobial resistance and resistance mechanisms also
change depending on the anatomical site [32e34]. It is also known
J. Soki et al. / Anaerobe 62 (2020) 1021826that the resistance elements for cefoxitin and tetracycline are
mobile so the mobility of the resistance elements for these anti-
biotics may also differ in the mucosal microbiota and feces. Transfer
regulations were described for the tetracycline resistance con-
jugative transposons of Bacteroides by tetracycline itself [35] and
for Tn916 of Firmicutes by ribosome targeting antibiotics [36], and
hence a similar differential regulation of horizontal spread is
anticipated in the intestine.
4. Conclusions
Overall, we can state the following points: (i) the antibiotic
susceptibilities of strains obtained from five European countries
were found to be similar to the previous European susceptibility
study on clinical Bacteroides group strains; (ii) exceptions were
noted for amoxicillin/clavulanate and clindamycin; and (iii) these
exceptions were most probably caused by temporal, spatial and
taxonomical differences, but differences in the anatomical origin
and thus between normalmicrobiota and clinical strains can also be
expected. We think that a more extensive, comparative investiga-
tion on the frequency of antibiotic resistance genes harboured by
these species will help us clarify this issue.
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